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Over the past years, mucosal healing has emerged as a major therapeutic goal in clinical trials in
inflammatory bowel diseases. Accumulating evidence indicates that mucosal healing may change
the natural course of the disease by decreasing the need for surgery and reducing hospitalization
rates in both ulcerative colitis and Crohn's disease. Mucosal healing may also prevent the
development of long-term disease complications, such as bowel damage in Crohn's disease and
colorectal cancer in ulcerative colitis. Histologic healing may be the ultimate therapeutic goal inof Gastroenterology and Hepatology, Campus Virchow Clinic, Charité, Universitätsmedizin Berlin,
Germany. Tel.: +49 30450565206; fax: +49 30450553929.
rite.de (A. Sturm).
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478 L. Peyrin-Biroulet et al.ulcerative colitis, whereas its impact on the course of Crohn's disease is unknown. Complete
mucosal healing may be required before considering drug withdrawal. Targeting early Crohn's
disease is more effective than approaches aimed at healing mucosa in longstanding disease.
Several questions remain to be answered: should mucosal healing be systematically used in
clinical practice? Should we optimize therapies to achieve mucosal healing? What is the degree of
intestinal healing that is required to change the disease course? Large prospective studies
addressing these issues are needed.
© 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.Contents
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the disease?
Key messages
- Mucosal healing is associated with lower relapse rates
- Mucosal healing is associated with lower hospitalization rates
- Mucosal healing is associated with less bowel damage (fistulas)
in Crohn's disease
- Mucosal healing is associated with reduced need for surgery
- Mucosal lesions predict postoperative clinical recurrence in
Crohn's disease
- Mucosal healing is associated with lower risk of colorectal
cancer in ulcerative colitis
Questions to be addressed in the future
- What is the impact of mucosal healing on bowel damage
(stricture, abscess and fistula) in Crohn's disease in prospec-
tive studies? What is the best timing for endoscopic
evaluation in the postoperative setting in Crohn's disease?
- What is the impact of mucosal healing on the risk of colorectal
cancer in Crohn's disease?1. Introduction
Over the past decades, several studies looked at mucosal
healing (MH) in inflammatory bowel diseases. The scientific
committee of ECCO has launched in 2010 a scientific workshop
that focused on this significant clinical research question. The
overall objective was to better understand and explore the
importance ofmucosal healing in inflammatory bowel disease.
The outcome of this workshop is presented into four parts:
Mechanisms of Intestinal Healing (Basic science), Measures and
Markers of Prediction to achieve, detect, and monitor
Intestinal Healing, Impact of Intestinal Healing on the Course
of IBD (Natural history), and Therapeutic Strategies to enhance
Intestinal Healing (Therapy). This manuscript summarizes
current knowledge regarding the impact of mucosal healing
on the course and management of inflammatory bowel
diseases and highlights several key issues that need to be
addressed in future studies.
2. How important is MH in the course of the
disease? (Table 1)
2.1. Is MH associated with better clinical response
rates?
With regard to Crohn's disease, D'Haens et al. reported in a
substudy of the ACCENT 1 trial that patients who wereachieving MH with infliximab had a longer relapse-free
survival than those patients whose MH was not reached.1 In a
retrospective single center cohort study reporting the long-
term outcome of infliximab in 214 patients with Crohn's
disease,2 patients achieving MH experienced a sustained
clinical benefit more frequently compared to patients who
Table 2 Should we adapt our therapy based on mucosal
healing?
Key messages
- Mucosal healing is associated with lower relapse rates following
drug withdrawal in infliximab-treated patients with Crohn's
disease
- Histologic healing is associated with better outcomes in
ulcerative colitis
- Greater mucosal healing rates are achieved in early Crohn's
disease
Questions to be addressed in the future
- Should therapies be optimized to achieve mucosal healing?
- Is sustained mucosal healing required to change the course of
the disease?
- What is the degree of mucosal healing that is required to
modify disease course?
- What is the impact of histologic healing on the course of Crohn's
disease?
- What is the impact of disease duration of mucosal healing rates
in ulcerative colitis?
479Impact of Mucosal healing on IBDdid not achieve MH after a median follow-up of 69 months
(64.8% vs. 39.5%, respectively, p=0.0004). Also, the long-
term follow-up of the step-up/top-down trial3,4 showed that
patients achieving MH at 2 years remained in steroid-free
clinical remission during the following 2 years more fre-
quently compared to patients with persistent endoscopic
activity at 2 years by combining the two treatment arms (71%
vs. 27%, respectively, p=0.003).
Already in 1966, Wright et al. reported that patients with
ulcerative colitis who did not achieve MH under oral and
rectal steroids relapsed more frequently during a follow-up
period of 1 year compared to patients who did achieve MH
(40% vs. 18%, respectively).5 In the ACT1 and ACT2 trials,6,7
the proportion of infliximab-treated patients with ulcerative
colitis in clinical remission at week 30 was fourfold greater
for patients with MH at week 8 (48.3% vs. 9.5%, respectively).
In a Japanese study including 56 patients who achieved
clinical remission after leukocytapheresis for ulcerative
colitis and followed-up during a median of 22 months,
significantly higher sustained clinical remission rates were
reported among patients who had also achieved MH.8 In an
Italian cohort enrolling patients with ulcerative colitis, those
not achieving endoscopic remission at 3 months had a higher
cumulative probability of clinical relapse (73.9 vs. 27.5%,
respectively, pb0.001).9
Data on MH in pediatric Crohn's disease and ulcerative
colitis are scarce.10 A retrospective pediatric study has
compared the effect of step-up and top-down strategies in 32
children with newly diagnosed Crohn's disease. The CDEIS
score was lower in patients receiving infliximab therapy (6.5)
than in those receiving non-biologic therapy (12.4) and the
rate of clinical relapse at 1 year was significantly lower in the
top-down group receiving infliximab therapy.11
A pediatric retrospective study looked at 37 children who
received exclusive enteral nutrition, comparing outcomes in
these children to those of 10 children treated with steroids.
Children managed with exclusive enteral nutrition achieved
greater MH (64.8% vs. 40%) and had a longer duration ofremission in the 12-month follow-up period.12 Data on MH in
pediatric ulcerative colitis are eagerly awaited.
MH is associatedwith higher clinical response and
lower rates of relapses in both Crohn's disease
and ulcerative colitis.
2.2. Is MH associated with fewer hospitalizations?
In the endoscopic substudy of the ACCENT I trial, patients
achieving MH at both weeks 10 and 54 needed less Crohn's
disease-related hospitalizations (0.0%) compared to those
with MH at only one of both visits (18.8%) or with no healing at
either visit (28.0%).13 In a retrospective single center cohort
study evaluating the long-term outcome of infliximab in 214
patients with Crohn's disease,2 patients who achieved MH
needed hospitalization less frequently compared to patients
who did not (42.2% vs. 59.3%, respectively, p=0.0018).
In ulcerative colitis, Ardizzone et al. showed that no MH
after first course of corticosteroid therapywas associatedwith
a more aggressive disease course. Indeed, after multivariate
analysis, lack of MH was the only factor associated with
negative outcomes at 5 years, including hospitalization (HR,
3.634; 95% CI, 1.556–8.485; P=0.0029).14
MH is associated with lower hospitalization rates
in both ulcerative colitis and Crohn's disease.
2.3. Does MH prevent complicated disease behavior
in Crohn's disease?
There is no or scarce data on the impact ofmucosal healing on
disease behavior in Crohn's disease. In a retrospective study
evaluating 102 patients with Crohn's disease, the presence of
deep ulcerations at index ileocolonoscopy was associated
with a higher risk of developing penetrating disease after a
median follow-up of 52 months (Log Rank p=0.003).15
Significant mucosal lesions at diagnosis might
indicate complicated disease behavior. However,
large prospective studies are needed to further
investigate whether MH may prevent complica-
tions in Crohn's disease.
2.4. Is MH associated with a reduced need for
surgery?
In Crohn's disease, the presence of deep ulcerations at
index ileocolonoscopy was associated with a higher risk of
surgical resections after a median follow-up of 52 months
(relative risk (95% CI): 5.43 (2.64–11.18), pb0.0001).15 In
a retrospective single center cohort study evaluating the
long-term outcome of infliximab in 214 patients with
Crohn's disease,2 patients who had achieved MH needed
major abdominal surgery less frequently than those who
480 L. Peyrin-Biroulet et al.did not achieve MH (14.1% vs. 38.4%, respectively,
pb0.0001). In a Norwegian population-based cohort
study,16 11% of Crohn's disease patients with MH at
1 year needed a surgical resection by 5 years compared
to 20% of patients without MH (p=0.10).
In 1980, Buckel et al.17 found that while there was a
tendency for anorexia, abdominal tenderness on palpa-
tion, fever, tachycardia, leukocytosis, and hypoproteine-
mia to occur more commonly as the depth of ulceration
increased in acute colitis, no single feature or combina-
tion of these features correlated well with ulcer depth.
More recently, in a French study,18 23% of the patients
without deep ulceration were submitted to surgery in
comparison to 93% of those with deep ulceration.
Subsequently, the same group confirmed that the pres-
ence of severe endoscopic lesions was independently
associated with increased colectomy rates in acute severe
ulcerative colitis.19 In another French study enrolling 118
patients with steroid-refractory ulcerative colitis, the
presence of severe endoscopic lesions was an independent
predictive factor of colectomy (adjusted hazard
ratio = 2.38, 95% confidence interval 1.80–3.14).20 A
Japanese study including patients with intravenous ste-
roid refractory ulcerative colitis found lower colectomy
rates at 1 year among subjects with mucosal improvement
at day 14 (pb0.01).21
Over the past years, some studies evaluated the impact of
mucosal lesions on the need for colectomy in ulcerative
colitis outside the setting of acute severe colitis. In a
retrospective single center study, a longer colectomy-free
survival was observed among ulcerative colitis patients who
achieved MH at week 4 or 10.22 In a substudy of the ACT1 and
ACT2 trials, a lower colectomy rate was reported within the
first 54 weeks of follow-up in patients with ulcerative colitis
randomized to infliximab compared to placebo (10% vs. 17%,
respectively, p=0.02).23 In a Norwegian population-based
cohort study,16 2% of ulcerative colitis patients with MH at
1 year needed a surgical resection by 5 years compared to 7%
of patients without MH (p=0.02). Ardizzone et al. showed
that the lack of MH after first course of corticosteroid
therapy was associated with higher need for colectomy in
newly diagnosed ulcerative colitis (HR, 8.397; 95% CI,
1.278–55.186; p=0.0268).14
MH is associated with a reduced need for surgery
in both Crohn's disease and ulcerative colitis.
2.5. Can MH predict clinical postoperative
recurrence in Crohn's disease?
In 1990, Rutgeerts et al. demonstrated in a prospective cohort
that endoscopic lesions within the first year after an
ileocolonic resection for Crohn's disease predicted postoper-
ative clinical recurrence.24 Throughout follow-up, symptom-
atic recurrence occurred less frequently in patientswho had no
severe endoscopic lesions at 1 year (Rutgeerts' score 0 or 1)
compared to patients with a more severe endoscopic
recurrence (Rutgeerts' score≥ i2).
In severe recurrent ileitis treated with azathioprine, the
therapy resulted in induction and maintenance of clinicalremission in all 15 patients. However, complete macroscopic
healing of the neoterminal ileum was observed in 6 patients,
near-complete healing with only superficial erosions remaining
in 5 patients, partial healing in 3 of 15 patients, and unchanged
inflammatory lesions in one patient, suggesting that partial
healing may be sufficient to prevent clinical recurrence.25
Yamamoto et al. investigated the impact of enteral
nutrition on clinical and endoscopic recurrence after surgical
resection for pediatric Crohn's disease26. Forty consecutive
patients who underwent resection for ileal or ileocolonic
Crohn's disease were randomized to receive partial enteral
nutrition or a regular diet. Twelve months after surgery,
endoscopic recurrence was observed in six patients (30%) in
the enteral nutrition group compared to 14 (70%) in the non-
enteral nutrition group (P=0.027). One patient (5%) in the
enteral nutrition group and 7 (35%) in the non-enteral nutrition
group developed clinical recurrence during the 1-year follow-
up (P=0.048) 26. Thus, long-term enteral nutrition supple-
mentation may significantly reduce clinical and endoscopic
recurrence after resection for Crohn's disease.
Endoscopic postoperative recurrence predicts a
worse outcome in Crohn's disease. However, the
optimal timing for endoscopic evaluation remains
unclear.
2.6. Is MH associated with less colorectal cancer?
In an epidemiological, case–control study including 68
patients with longstanding extensive ulcerative colitis who
were matched to 136 controls, histological inflammation
score was the only independent risk factor for the develop-
ment of colorectal neoplasia (Odds ratio (95% CI): 4.69 (2.10–
10.48), pb0.001).27 In a subsequent study, Rutter et al.
showed that macroscopically normal endoscopic findings
returned the 5-year cancer risk to that of the general
population (Odds ratio (95% CI): 0.38 (0.19–0.73),
p=0.003).28 Rubin et al. also demonstrated a higher risk of
cancer and dysplasia in ulcerative colitis patients with a
higher inflammatory activity score (Odds ratio (95% CI): 2.73
(1.44–5.18), p=0.002).29 Gupta et al. confirmed that
histological inflammation over time was associated with the
progression towards advanced neoplasia in ulcerative colitis
(Hazard ratio 3.0; 95% CI : 1.4–6.3).30
MH is associated with a lower risk of colorectal
cancer in ulcerative colitis. Such data is lacking in
Crohn's disease.
3. Should we adapt our therapy based on MH?
(Table 2)
3.1. CanMHbeused to optimize diseasemanagement
outcomes?
The GETAID31 demonstrated that in Crohn's disease patients
who had achieved clinical remission, adjustment of steroid
481Impact of Mucosal healing on IBDtreatment duration on the basis of endoscopic results
presented no benefit, and that the endoscopic aspect had
no prognostic value.
In the ACCENT 1 trial, Crohn's disease patients (n=9) who
had MH at both weeks 10 and 54 did not require any
hospitalization. Interestingly, patients with MH at only one
visit required fewer hospitalizations (18.8%) compared to
those without MH at both visits (28%), highlighting sustained
MH as a new therapeutic goal in Crohn's disease.13
Although MH, at least under anti-TNF-a therapy
is associated with fewer hospitalisations, the
question whether therapies should be optimized
based on endoscopic evaluation to improve
disease outcomes remains open and will require
further investigation.
3.2. Is MH associated with less relapse after drug
withdrawal?
In a placebo-controlled study by the GETAID including 83
patients in clinical remission under azathioprine, presence
of ulcerations at ileocolonoscopy before discontinuation of
azathioprine was not predictive for clinical relapse.32
Recently, in another GETAID trial, Louis et al. assessed the
risk of clinical relapse after discontinuation of infliximab in
109 patients with Crohn's disease who were in clinical
remission under a combined maintenance therapy with
infliximab and an immunomodulator (azathioprine or
methotrexate).33 In multivariate analysis, in contrast to
the former study investigating relapse after azathioprine
withdrawal, complete MH was among the factors strongly
associated with a decreased risk of clinical relapse after
infliximab withdrawal (Hazard ratio (95% CI): 2.6 (1.3–
5.3), p=0.005). In this study, immunosuppression with
azathioprine or methotrexate was continued.
In Crohn's disease, MH is associated with a
lower relapse rate after drug withdrawal, even
though this may depend on the type of drug.
The degree of mucosal healing which needs to
be achieved remains to be determined. With
regard to ulcerative colitis, such data is lacking.
3.3. What is the impact of the degree of intestinal
healing on disease course?
Importantly, Schnitzler et al.2 have shown that MH predicts
long-term outcome with maintenance therapy with inflix-
imab in Crohn's disease. The need for surgery was
significantly different between the groups with and without
MH (14% and 38.4%, respectively, pb0.0001). Interestingly,
there was no difference between the groups with complete
and partial MH (14% vs. 14.1%, respectively).
There is good evidence that infliximab can lead to
histological improvement in mucosal biopsies in Crohn's
disease. Di Sabatino et al.34 examined the effect of infliximabin Crohn's disease patients 10 weeks after treatment initia-
tion. Six out of 10 patients had clinical response and this
correlated well with macrophage matrix metalloproteinase
(MMP) expression levels in the mucosal biopsies along with
histological score improvement (2.66+/−0.51 at baseline to
0.16+/−0.40 at week 10). Non responders (n=4) conversely
revealed no histological improvement. Similarly, D'Haens et
al. have shown a good correlation between histological and
endoscopic healing after infliximab in a EuropeanMulticentre
trial.35 The CDEIS correlated with histological score 4 weeks
after infliximab therapy (r=0.56, p=0.002). However, the
impact of histological healing among infliximab-treated
patients with Crohn's disease is unknown.
Patients with ulcerative colitis whowere in clinical remission
but with histological evidence of mucosal inflammation (acute
inflammatory cell infiltrate, crypt abscess or mucin depletion)
had a 2–3 fold greater risk for clinical relapse during a 1-year
follow-up period compared to those with histological healing.36
In another study among ulcerative colitis patients,37 basal
plasmacytosis on rectal biopsy was as an independent predictor
of clinical relapse during a 1-year follow-up period (hazard ratio
(95% CI): 4.5 (1.7–11.9), p=0.003).
Whether complete or partial MH is required to
modify the disease course will require further
investigation. Histologic healing is associated
with a better outcome in ulcerative colitis, whereas
its impact on disease course remains to be
investigated in Crohn's disease.
3.4. What is the impact of disease duration and
disease extent on MH rates?
In the EXTEND trial, among 123 Crohn's disease patients with
mucosal ulceration at baseline, the rate of MH at week 12was
higher in subjects with disease duration less than 2 years than
in those with disease duration greater than 5 years (44 vs.
21%, respectively) in the adalimumab arm.38
D'Haens et al. found similar rates of complete MH in the
ileum and in the colon of Crohn's disease patients under
azathioprine for at least 9 months.39 In the IBSEN population-
based cohort, disease extension and location did not
influence MH rates in Crohn's disease patients.16 By contrast,
patients with extensive disease were more prone to reach MH
as compared to those with left-sided colitis and proctitis.16
The relationship between disease extension and mucosal
healing in this study may be partly explained by a more
aggressive treatment in patients with extensive colitis. Rates
of MH according to disease extent could not be investigated
in randomized, controlled trials as mucosal lesions are
usually assessed by proctosigmoidoscopy in ulcerative colitis.
Greater MH rates may be achieved in early
Crohn's disease, even though only data from
subgroup analyses are available. The impact of
disease duration on MH has never been investi-
gated in ulcerative colitis.
482 L. Peyrin-Biroulet et al.4. Conclusion
MH is associated with better outcomes in inflammatory
bowel diseases (clinical response/remission, hospitaliza-
tions, surgery). Some evidence indicates that MH may also
reduce the development of bowel damage such as fistulas in
Crohn's disease and the incidence of colorectal cancer in
ulcerative colitis. Several issues remain unresolved. Should
MH be systematically assessed to improve disease outcomes?
In this regard, large prospective studies assessing the impact
of MH and histologic healing on the natural course of
inflammatory bowel diseases in the era of biologics are
eagerly awaited. Another question remains open: should we
optimize therapies based on endoscopic findings to change
the disease course? Lastly, the timing of endoscopic
evaluation and the concept of sustained MH will also require
further investigation.
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